Dr. Esteva on the Future of Biosimilars in Breast Cancer

Video

Francisco J. Esteva, MD, PhD, director, breast medical oncology program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, discusses the future use of biosimilars in breast cancer within the United States.

Francisco J. Esteva, MD, PhD, director, breast medical oncology program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, discusses the future use of biosimilars in breast cancer within the United States.

Biosimilars have been widely used and adopted in Europe in a variety of disciplines, says Esteva. Although there appears to be more reluctance in the United States to introduce biosimilar therapy, providers and patients alike in both the United States and Europe are comfortable with the use of biosimilar products in supportive care, such as granulocyte-colony stimulating factor.

There is more apprehension regarding the use of biosimilars in the context of therapeutic monoclonal antibodies, he explains. However, based on what has been seen in other countries, he feels optimistic that they will increasingly be used in this space as well in the future.

In Europe, biosimilars have been shown to reduce the cost of expensive medications in certain areas of medicine by up to 30%, says Esteva. Due to these cost savings, Esteva expects the use of these products to increase substantially in the future.

Related Videos
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center